CD34+ peripheral blood progenitors as a target for genetic correction of the two flavocytochrome b558 defective forms of chronic granulomatous disease.
F Li, G F Linton, S Sekhsaria...
https://pubmed.ncbi.nlm.nih.gov/7517218/Actively Recruiting
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-08-11
850
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to collect CD34 hematopoietic stem cells HSC from peripheral blood andor bone marrow, along with mononuclear cells and granulocytes from peripheral blood. These cells will be used in laboratory studies and clinical treatments to develop new cell therapies for patients with inherited or acquired immune or blood disorders. The study includes adult patients with primary immune deficiencies or blood disorders and healthy adult volunteers to support the development and scale-up of gene therapies and cell engineering products. The main collection method for HSC is apheresis from peripheral blood after mobilization with daily subcutaneous injections of granulocyte colony stimulating factor G-CSF for 5 to 6 days, sometimes combined with Plerixafor. Some patients may also undergo bone marrow aspiration for clinical or research purposes. Mononuclear cells and granulocytes are collected from peripheral blood by apheresis, with or without pre-treatment using G-CSF alone or combined with dexamethasone, following standard care practices. Collected cells from patients may be used for clinical treatments under separate protocols or for laboratory research, while cells from healthy volunteers are used for research only. Participants provide blood andor bone marrow samples that may be stored or modified for research. Assessments include monitoring cell mobilization and collection through apheresis and bone marrow harvests. The collected cells contribute to laboratory studies of immune deficiencies, stem cell biology, and gene therapy development. The study evaluates the ability to mobilize and collect these cells safely and effectively. Participation involves collection visits and allows for ongoing research and potential clinical use of the samples in approved protocols.
CONDITIONS
Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes
J
Joanna L Peterson
H
Harry L Malech, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies by participant
Participants receive injections to mobilize stem cells and then undergo blood cell collection through apheresis or bone marrow aspiration for research or clinical use.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
F Li, G F Linton, S Sekhsaria...
https://pubmed.ncbi.nlm.nih.gov/7517218/H L Malech, P B Maples, N Whiting-Theobald...
https://pubmed.ncbi.nlm.nih.gov/9342375/S Sekhsaria, T A Fleisher, S Vowells...
https://pubmed.ncbi.nlm.nih.gov/8704221/National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor